Table 1.
Clinicalpathological implications of BAG2 expression in gastric patients.
| n (%) | BAG2 expression | P-value | ||
|---|---|---|---|---|
| High (%) | Low (%) | |||
| Gender | 0.48 | |||
| Male | 141 (74.6) | 70 (49.6) | 71 (50.4) | |
| Female | 48 (25.4) | 21 (43.8) | 27 (56.3) | |
| T stage | 0.002 | |||
| T1 | 4 (2.1) | 1 (25.0) | 3 (75.0) | |
| T2 | 27 (14.3) | 12 (44.4) | 15 (55.6) | |
| T3 | 27 (14.3) | 22 (81.5) | 5 (18.5) | |
| T4 | 131 (69.3) | 56 (42.7) | 75 (57.3) | |
| N status | 0.501 | |||
| N0 | 64 (31.2) | 33 (56.2) | 31 (43.8) | |
| N1–3 | 125 (68.8) | 58 (32.3) | 67 (67.7) | |
| M stage | 0.554 | |||
| M0 | 146 (77.2) | 72 (49.3) | 74 (50.7) | |
| M1 | 43 (22.8) | 19 (44.2) | 24 (55.8) | |
| Clinical stage | 0.24 | |||
| I | 17 (9.0) | 9 (52.9) | 8 (47.1) | |
| II | 24 (12.7) | 16 (66.7) | 8 (33.3) | |
| III | 105 (55.6) | 47 (44.8) | 58 (55.2) | |
| IV | 43 (22.8) | 19 (44.2) | 24 (55.8) | |
| Differentiation | 0.002 | |||
| Well | 19 (10.1) | 11 (57.9) | 8 (42.1) | |
| Moderately | 45 (23.8) | 31 (68.9) | 14 (31.1) | |
| Poorly | 125 (66.1) | 49 (39.2) | 76 (60.8) | |